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Sir,
We were interested to read a recent article by Vasey et al (2006)
in which the authors expressed some concern about the incidence
of pulmonary toxicity (Ptox) in patients treated with a taxane–
gemcitabine regimen, an issue that has been raised by several
others (Thomas et al, 2000; Bhatia et al, 2002; Harries et al, 2004).
The rare specific adverse drug reactions (ADRs) classified as Ptox
are known to occur with the use of gemcitabine (Gem) and both
taxanes, docetaxel (Doc) and paclitaxel (Pac). All three drugs are
used as single agents and increasingly in combination treatment.
In order to evaluate whether these combinations have greater
Ptox than single agents, the Eli Lilly spontaneous safety database
(LSD) was searched for MedDRA terms (pulmonary oedema, acute
respiratory distress syndrome (ARDS), dyspnoea and pneumonitis
NOS) for Gem and Gemþtaxane combinations. All of these
reactions are listed in the relevant product information. Identified
Ptox reports were reviewed individually and as aggregate data. In
addition, Proportional Reporting Ratios (PRRs) were calculated
from the FDA Freedom of Information (FDA-FOI) database;
similar PRR calculations were also performed from the LSD (12
January 1998 to 30 June 2004). Proportional Reporting Ratios
compare rates of events observed with one particular drug with the
rates of the same events that may be expected with exposure to all
drugs in the database (Evans et al, 2001) and reflect the strength of
association between a drug and an event.
Pulmonary toxicity ADRs reported to Lilly in patients treated with
Gemþtaxane combinations were compared to those reported in
patients receiving Gem monotherapy. An aggregate review did not
provide evidence of a different Ptox safety profile for Gem used alone
or in combination with taxanes. PRRs from the LSD for Gemþtaxane
combinations and Gem alone showed a similar trend (data not
shown), which could indicate similar Ptox profiles for all three drugs.
The PRR calculations for Ptox for Gemþtaxane combinations
and for Gem and the taxanes alone, calculated from the FOI
database, show broadly similar patterns for the terms that are
included in the labels of all three drugs (ARDS Gem 9.37, Doc 6.81,
Pac 1.97; Pulmonary Oedema Gem 2.20, Doc 1.99, Pac 2.64;
Dyspnoea Gem 3.09, Doc 1.79, Pac 1.61; Pneumonitis NOS Gem
9.52, Doc 9.63, Pac 3.70). It must be noted that PRRs reflect the
strength of association but there is no linear relationship between
the PRR value and the association between drug and event; values
over 1 indicate the association and values of at least 2 are generally
accepted as indicating a possible safety signal (Evans et al, 2001).
Any potential for additive toxicity of the drugs used in
combination (specifically for pneumonitis) may be due to both
components (GemþDoc ARDS 4.32, Pulmonary Oedema 3.07,
Dyspnoea 1.91, Pneumonitis 21.94; GemþPac ARDS 1.03,
Pulmonary Oedema 2.32, Dyspnoea 2.08, Pneumonitis 15.97).
The FOI database contains larger numbers of drugs and events,
and therefore higher numerators and denominators, than the LSD
that results in lower ratios in general.
The review of Ptox cases indicated that there was no substantial
difference in Ptox reported with the combination of Gem
and taxanes in comparison to Gem alone. The strength of
association (PRRs) with respect to Ptox calculated on data
from the LSD and the FDA-FOI database support this finding.
In addition, PRR calculations for taxanes on the FDA-FOI database
seemed to indicate a similar safety profile (PTox) for all
three drugs. Therefore, any potential increase in toxicity of
these drugs used in combination seems to be due to both
components of the combination (additive toxicity). The PRRs were
calculated here for taxanes with and without gemcitabine, they
were not calculated for combinations of taxanes and other
chemotherapeutic agents.
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